Related Experiment Video
Updated: Jul 1, 2026

A Quantitative Detection Method for MicroRNAs in the Kidney of an Ischemic Kidney Injury Mouse Model
Published on: September 11, 2020
Urinary sediment mRNA as a potent biomarker of IgA nephropathy
Jin Sug Kim1, Geon Woo Kim1, Hyeon Seok Hwang1
1Division of Nephrology, Department of Internal Medicine, Kyung Hee University College of Medicine, Kyung Hee University Medical Center, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Republic of Korea.
Background:
The quantification of mRNA expression in urinary sediments is a reliable biomarker for various diseases. However, few studies have investigated the clinical relevance of urinary mRNA levels in IgA nephropathy (IgAN). Thus, we investigated the expression of urinary mRNAs and their clinical significance in IgAN.
Methods:
Overall, 200 patients with biopsy-proven IgAN, 48 disease controls, and 76 healthy controls were enrolled. We identified the differential expression of mRNAs in renal tissue between patients with IgAN and normal subjects using the Gene Expression Omnibus dataset and selected candidate mRNAs. mRNA expression in the urinary sediment was measured using quantitative real-time polymerase chain reaction. Associations between urinary mRNA levels and clinicopathological parameters were analyzed and the predictive value of mRNAs for disease progression was evaluated.
Results:
The urinary expression of CCL2, CD14, DNMT1, FKBP5, Nephrin, and IL-6 was significantly upregulated in patients with IgAN compared with healthy controls. C3, FLOT1, and Podocin levels were significantly correlated with renal function, where C3, FLOT1, and TfR levels were significantly correlated with urinary protein excretion. During follow-up, 26 (13.0%) patients with IgAN experienced disease progression, defined as a greater than 50% reduction in the estimated glomerular filtration rate or progression to end-stage renal disease. Urinary mRNA levels of FLOT1 (HR 3.706, 95% CI 1.373-10.005, P = 0.010) were independently associated with an increased risk of disease progression.
Conclusions:
Our results suggest that urinary sediment mRNAs are a useful biomarker in IgAN patients. Further studies with larger sample sizes and longer follow-up durations are required.
Insights
Urinary mRNA levels, including FLOT1, show promise as biomarkers for IgA nephropathy (IgAN) progression. This research highlights their potential clinical relevance in managing IgAN patients.
Area of Science:
- Nephrology
- Molecular Biology
- Biomarker Discovery
Background:
- Urinary mRNA quantification is a recognized biomarker for disease.
- Limited research exists on urinary mRNA in IgA nephropathy (IgAN).
- This study explores urinary mRNA expression and clinical significance in IgAN.
Purpose of the Study:
- To investigate urinary mRNA expression in IgA nephropathy (IgAN).
- To determine the clinical significance of urinary mRNA levels in IgAN.
- To evaluate the predictive value of urinary mRNAs for IgAN disease progression.
Main Methods:
- Analyzed Gene Expression Omnibus data for differential mRNA expression in IgAN renal tissue.
- Quantified urinary sediment mRNA using quantitative real-time polymerase chain reaction in 200 IgAN patients, 48 disease controls, and 76 healthy controls.
- Assessed associations between urinary mRNA levels and clinicopathological parameters, and evaluated predictive value for disease progression.
Main Results:
- Upregulated urinary expression of CCL2, CD14, DNMT1, FKBP5, Nephrin, and IL-6 in IgAN patients versus healthy controls.
- Correlations found between C3, FLOT1, Podocin, and TfR levels with renal function and urinary protein excretion.
- Urinary FLOT1 mRNA levels independently predicted increased risk of IgAN disease progression (HR 3.706, P=0.010).
Conclusions:
- Urinary sediment mRNAs serve as valuable biomarkers for IgA nephropathy (IgAN).
- Further validation with larger cohorts and extended follow-up is warranted.
Related Concept Videos
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Nephrotic Syndrome II : Assessment and Medical Management
Urine Studies I: Urinalysis

